Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Connect Biopharma Holdings Limited before investing.

In this article, we go over a few key elements for understanding Connect Biopharma Holdings Limited’s stock price such as:

• Connect Biopharma Holdings Limited’s current stock price and volume
• Why Connect Biopharma Holdings Limited’s stock price changed recently
• Upgrades and downgrades for CNTB from analysts
• CNTB’s stock price momentum as measured by its relative strength

About Connect Biopharma Holdings Limited (CNTB)

Before we jump into Connect Biopharma Holdings Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Want to learn more about Connect Biopharma Holdings Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Connect Biopharma Holdings Limited.

Connect Biopharma Holdings Limited’s Stock Price as of Market Close

As of May 20, 2026, 4:00 PM, CST, Connect Biopharma Holdings Limited’s stock price was $2.310.

Connect Biopharma Holdings Limited is up 5.48% from its previous closing price of $2.190.

During the last market session, Connect Biopharma Holdings Limited’s stock traded between $2.190 and $2.380. Currently, there are approximately 56.55 million shares outstanding for Connect Biopharma Holdings Limited.

Connect Biopharma Holdings Limited’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Connect Biopharma Holdings Limited Stock Price History

Connect Biopharma Holdings Limited’s (CNTB) price is currently down 6.48% so far this month.

During the month of May, Connect Biopharma Holdings Limited’s stock price has reached a high of $2.700 and a low of $2.190.

Over the last year, Connect Biopharma Holdings Limited has hit prices as high as $3.820 and as low as $1.230. Year to date, Connect Biopharma Holdings Limited’s stock is down 18.09%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Connect Biopharma Holdings Limited Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 19, 2026, there were analysts who downgraded Connect Biopharma Holdings Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Connect Biopharma Holdings Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Connect Biopharma Holdings Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Connect Biopharma Holdings Limited’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Connect Biopharma Holdings Limited (CNTB) by visiting AAII Stock Evaluator.

Relative Price Strength of Connect Biopharma Holdings Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 19, 2026, Connect Biopharma Holdings Limited has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Connect Biopharma Holdings Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Connect Biopharma Holdings Limited Stock Price: Bottom Line

As of May 20, 2026, Connect Biopharma Holdings Limited’s stock price is $2.310, which is up 5.48% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Connect Biopharma Holdings Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.